Expert Opinion on Biological Therapy 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - March 14, 2024 Category: Drugs & Pharmacology Authors: Hong De SaRichard T. MaziarzArpita P. GandhiCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA Source Type: research
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - March 6, 2024 Category: Drugs & Pharmacology Authors: Paolo DapavoMartina BurlandoClaudio GuarneriMatteo MegnaAlessandra NarcisiMarina TalamontiPaolo Gisondia Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italyb Clinica Dermatologica Ospedale Policlinico San Martino - IR Source Type: research
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - March 4, 2024 Category: Drugs & Pharmacology Authors: Gabriele RoccuzzoEleonora GherardiMichele MaioPiergiorgio MalagoliAngelo Valerio MarzanoAurora ParodiNicola PimpinelliFrancesco SpagnoloAnna Maria Di GiacomoPietro Quaglinoa Department of Medical Sciences, Section of Dermatology, University of Turin, Turi Source Type: research
More failure with solanezumab – this time in preclinical Alzheimer’s disease
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - March 4, 2024 Category: Drugs & Pharmacology Authors: Sheila A DoggrellSchool of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia Source Type: research
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 28, 2024 Category: Drugs & Pharmacology Authors: Anan S. JarabShrouq R. Abu HeshmehAhmad Z. Al Meslamania College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emiratesb AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emiratesc Pharmacy, Jordan University of Source Type: research
Targeting cervical cancer with anti-PD-1 antibodies: what is new?
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 28, 2024 Category: Drugs & Pharmacology Authors: Michelle GreenmanBlair McNamaraLevent MutluAlessandro D. SantinDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT, USA Source Type: research
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 28, 2024 Category: Drugs & Pharmacology Authors: Lukas PekarSimon KrahStefan Zielonkaa Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germanyb Biomolecular Immunotherapy, Institute for Organic Chemistry and Biochemistry, Technische Universit ät Darmstadt, Darmstadt, German Source Type: research
Clinical use of biologics for Crohn ’s disease in adults: lessons learned from real-world studies
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Antonio TursiGiammarco MocciAngelo Del GaudioAlfredo Papaa Territorial Gastroenterology Service, ASL BAT, Andria, Italyb Department of Medical and Surgical Sciences, Catholic University, School of Medicine, Rome, Italyc Division of Gastroenterology, “Br Source Type: research
Streamlining biosimilar development based on 20 years ’ experience
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Cecil NickParexel International, Uxbridge, Middlesex, England Source Type: research
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Na-Qiong WuZhi-Fan LiMeng-Ying LuJian-Jun LiCardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China Source Type: research
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT ‑P41 and reference denosumab in healthy males
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Anhye KimJang Hee HongWonsuk ShinHyounggyoon YooJin-Gyu JungJean-Yves ReginsterSungHyun KimYunJu BaeJeeHye SuhSera KimEunKyung LeeStuart Silvermana Department of Clinical Pharmacology and Therapeutics, CHA University School of Medicine, Seongnam, Republic Source Type: research
Epcoritamab in B-cell malignancies: current status and prospects
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 12, 2024 Category: Drugs & Pharmacology Authors: Stefano MolicaMarco RossiDavid Allsupa Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UKb Department Haematology, Azienda Ospedaliera-Universitaria “Renato Dulbecco”, Catanzaro, Italyc Università Ma Source Type: research
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 2, 2024 Category: Drugs & Pharmacology Authors: Kamila PolgarovaMarek Trnenya First Department of Internal Medicine-Hematology, General University Hospital, Prague, Czech Republicb First Medicine, Charles University, Prague, Czech Republic Source Type: research
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - January 31, 2024 Category: Drugs & Pharmacology Authors: Julia Lang-MeliChristoph Neumann-HaefelinRobert Thimmea Department of Medicine II, Medical Center – University of Freiburg and Faculty of Medicine, University Hospital Freiburg, Freiburg, Germanyb IMM-PACT Programm, Faculty of Medicine, University Hospi Source Type: research
The latest advances in the use of biological DMARDs to treat Still ’s disease
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - January 29, 2024 Category: Drugs & Pharmacology Authors: Ilenia Di ColaPiero RuscittiDepartment of Biotechnological and Applied Clinical Sciences, University of L ’Aquila, L’Aquila, Italy Source Type: research
